Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Teva Pharmaceutical Industries ADR (TEVA)

Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,025,962
  • Shares Outstanding, K 1,132,909
  • Annual Sales, $ 15,846 M
  • Annual Income, $ -559,000 K
  • EBIT $ 1,681 M
  • EBITDA $ 2,834 M
  • 60-Month Beta 0.79
  • Price/Sales 1.52
  • Price/Cash Flow 6.06
  • Price/Book 3.78

Options Overview Details

View History
  • Implied Volatility 39.96% ( +5.45%)
  • Historical Volatility 73.13%
  • IV Percentile 50%
  • IV Rank 32.72%
  • IV High 66.54% on 12/16/24
  • IV Low 27.03% on 06/11/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 113,392
  • Volume Avg (30-Day) 61,272
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 981,609
  • Open Int (30-Day) 814,472

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.66
  • Number of Estimates 5
  • High Estimate 0.69
  • Low Estimate 0.63
  • Prior Year 0.98
  • Growth Rate Est. (year over year) -32.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.25 +35.94%
on 12/13/24
22.17 -0.36%
on 12/20/24
+5.06 (+29.71%)
since 11/20/24
3-Month
16.15 +36.78%
on 11/18/24
22.17 -0.36%
on 12/20/24
+4.58 (+26.16%)
since 09/20/24
52-Week
10.34 +113.64%
on 12/26/23
22.17 -0.36%
on 12/20/24
+11.68 (+112.20%)
since 12/20/23

Most Recent Stories

More News
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...

MRK : 98.05 (-1.48%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
My Top 10 Portfolio Holdings for 2025

This combination of growth and value stocks has the potential to outperform the broader market in 2025 (and beyond).

PYPL : 87.13 (+0.40%)
COMP : 6.23 (+4.18%)
META : 585.25 (-1.73%)
LOVE : 23.93 (+2.18%)
BAC : 44.17 (+1.82%)
PUBM : 15.44 (+0.26%)
AG : 5.46 (+0.18%)
BARK : 1.9800 (+2.59%)
TEVA : 22.09 (+3.66%)
PINS : 29.49 (-0.41%)
SSRM : 6.95 (+1.16%)
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...

JNJ : 144.47 (+0.62%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
SNY : 47.71 (+0.44%)
Teva and Sanofi Announce Phase 2b Study Success for Duvakitug in Treating Ulcerative Colitis and Crohn's Disease

Phase 2b study confirms duvakitug's efficacy in ulcerative colitis and Crohn’s disease, advancing towards Phase 3 development.Quiver AI SummaryTeva Pharmaceuticals and Sanofi announced that their Phase...

TEVA : 22.09 (+3.66%)
Teva Stock Surges To 6-Year High On Inflammatory Bowel Disease Drug Trial Data: Retail Chatter Erupts

Investors are now eyeing duvakitug’s potential to become a significant revenue driver for both companies, especially as there is currently no cure for IBD.

TEVA : 22.09 (+3.66%)
SNY : 47.71 (+0.44%)
Teva Pharmaceutical Industries Ltd. Enters Agreement to Divest Teva-Takeda Business Venture in Japan to JKI Co., Ltd.

Teva has agreed to divest its Japanese business, Teva-Takeda, to JKI, focusing on innovative medicines.Quiver AI SummaryTeva Pharmaceutical Industries Ltd. has announced an agreement with JKI Co., Ltd.,...

TEVA : 22.09 (+3.66%)
Teva Pharmaceuticals Reports Positive Phase 3 Results for AJOVY® (fremanezumab) in Reducing Migraine Days in Pediatric Patients Aged 6-17

AJOVY® (fremanezumab) reduces migraine days in children, showing efficacy and safety in a Phase 3 study.Quiver AI SummaryTeva Pharmaceutical Industries has announced positive results from its Phase 3...

TEVA : 22.09 (+3.66%)
Is SoundHound AI a Millionaire-Maker Stock?

A tiny company in a fast-growing industry is a recipe for millionaire-making potential. And with shares up by a whopping 347% year to date as of this writing, SoundHound AI (NASDAQ: SOUN) has been a top...

STLA : 12.89 (+0.39%)
SOUN : 21.75 (+15.38%)
BNPQY : 29.9700 (-0.03%)
TEVA : 22.09 (+3.66%)
FJTSY : 18.0000 (+1.64%)
TEVA Stock Down 10% in a Month: Should You Buy the Dip?

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well as sales....

JNJ : 144.47 (+0.62%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
SNY : 47.71 (+0.44%)
2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

LXRX : 0.7147 (-1.23%)
VTRS : 12.52 (+3.22%)
TEVA : 22.09 (+3.66%)
AMGN : 263.38 (+0.84%)
PFE : 26.36 (+2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets,...

See More

Key Turning Points

3rd Resistance Point 23.53
2nd Resistance Point 22.85
1st Resistance Point 22.47
Last Price 22.09
1st Support Level 21.41
2nd Support Level 20.73
3rd Support Level 20.35

See More

52-Week High 22.17
Last Price 22.09
Fibonacci 61.8% 17.65
Fibonacci 50% 16.26
Fibonacci 38.2% 14.86
52-Week Low 10.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar